DISCOVERY OF NOVEL 4-AMINOPTERIDINE DERIVATIVES AS EGFR INHIBITORS: AN IN SILICO APPROACH
Bulletin of Pharmaceutical Research · 2024-12 · 14 (3)
DOI: 10.21276/bpr.2024.14.3.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Pharmaceutical Research, 2024-12. Verfasst von Shah AP.
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) is a member of the ErbB family of the receptor tyrosine kinase that plays crucial role in many different cells signaling pathways. EGFR overexpression leads to the growth of cancerous cells. As a result, EGFR is considered as one of the key targets for cancer therapy. In this study, ten novel 4-amino pteridine derivatives were designed and in silico studies were performed to find out novel hits as EGFR inhibitors. The in silico methods includes molecular docking studies, druglikeness screening, in silico toxicity screening and bioactivity prediction. All the designed compounds had druglikeness properties and showed no violations as per the Lipinski rule. In docking studies, three compounds QZ7, QZ8 and QZ10 were found which had higher binding affinity as compared to standard drug, lapatinib. Bioactivity prediction of designed compounds suggested that all the compounds may act through kinase inhibition. Out of the ten compounds, three compounds QZ7, QZ8 and QZ10 were found with good potential to be explored as EGFR inhibitors.
Zitieren
APA
AP, S. (2024). DISCOVERY OF NOVEL 4-AMINOPTERIDINE DERIVATIVES AS EGFR INHIBITORS: AN IN SILICO APPROACH. Bulletin of Pharmaceutical Research, 14(3). https://doi.org/10.21276/bpr.2024.14.3.3
Vancouver
AP S. DISCOVERY OF NOVEL 4-AMINOPTERIDINE DERIVATIVES AS EGFR INHIBITORS: AN IN SILICO APPROACH. Bulletin of Pharmaceutical Research. 2024;14(3). doi:10.21276/bpr.2024.14.3.3
BibTeX
@article{AP2024,
author = {AP, Shah},
title = {DISCOVERY OF NOVEL 4-AMINOPTERIDINE DERIVATIVES AS EGFR INHIBITORS: AN IN SILICO APPROACH},
journal = {Bulletin of Pharmaceutical Research},
year = {2024},
volume = {14},
number = {3},
doi = {10.21276/bpr.2024.14.3.3}
}
EUVIMED